Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Congenital enterocyte heparan sulfate deficiency is characterized by massive enteric protein loss, secretory diarrhea, and intolerance to enteral feeds during the first few weeks of life.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for congenital enterocyte heparan sulfate deficiency.
2 publications have been identified in PubMed for congenital enterocyte heparan sulfate deficiency. Research spans Review / Meta-Analysis (100%).
Liu X (2026). [PMID: 41832306](https://pubmed.ncbi.nlm.nih.gov/41832306/). *Mol Biomed*. [Review / Meta-Analysis]
Lalande A (2025). [PMID: 40498321](https://pubmed.ncbi.nlm.nih.gov/40498321/). *FEMS Microbiol Rev*. [Review / Meta-Analysis]
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 9:05 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about congenital enterocyte heparan sulfate deficiency